Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-15

Clinical Trial Update: Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing chloroprocaine 2% to ropivacaine 0.75% for ultrasound-guided axillary nerve block completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Chloroprocaine 2% (chloroprocaine)
  • Ropivacaine 0.75% (Ropivacaine)

Snippet

Sponsor: Sintetica SA | Conditions: Axillary Nerve Block | Phase 3 | Status: COMPLETED | Results posted: 2021-07-15